About: Impact of corticosteroid treatment on clinical outcomes of influenza-associated ARDS: a nationwide multicenter study

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Impact of corticosteroid treatment on clinical outcomes of influenza-associated ARDS: a nationwide multicenter study Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Impact of corticosteroid treatment on clinical outcomes of influenza-associated ARDS: a nationwide multicenter study
Creator	Hu, Han-Chung Kao, Kuo-Chin Wu, Chieh-Liang Tsai, Ming-Ju Chan, Ming-Cheng Chang, Wei-An Chao, Wen-Cheng Chen, Wei-Chih Chien, Ying-Chun Fang, Wen-Feng Liang, Shinn-Jye Lin, Chiung-Yu Perng, Wann-Cherng Sheu, Chau-Chyun Tsai, Jong-Rung Wang, Hao-Chien Yang, Kuang-Yao
Source	PMC
abstract	BACKGROUND: Corticosteroid treatment has been widely used in the treatment of septic shock, influenza, and ARDS, although some previous studies discourage its use in severe influenza patients. This multicenter retrospective cohort study conducted in the intensive care units (ICUs) of eight medical centers across Taiwan aims to determine the real-world status of corticosteroid treatment in patients with influenza-associated acute respiratory distress syndrome (ARDS) and its impact on clinical outcomes. Between October 2015 and March 2016, consecutive ICU patients with virology-proven influenza infections who fulfilled ARDS and received invasive mechanical ventilation were enrolled. The impact of early corticosteroid treatment (≥ 200 mg hydrocortisone equivalent dose within 3 days after ICU admission, determined by a sensitivity analysis) on hospital mortality (the primary outcome) was assessed by multivariable logistic regression analysis, and further confirmed in a propensity score-matched cohort. RESULTS: Among the 241 patients with influenza-associated ARDS, 85 (35.3%) patients receiving early corticosteroid treatment had similar baseline characteristics, but a significantly higher hospital mortality rate than those without early corticosteroid treatment [43.5% (37/85) vs. 19.2% (30/156), p < 0.001]. Early corticosteroid treatment was independently associated with increased hospital mortality in overall patients [adjusted odds ratio (95% CI) = 5.02 (2.39–10.54), p < 0.001] and in all subgroups. Earlier treatment and higher dosing were associated with higher hospital mortality. Early corticosteroid treatment was associated with a significantly increased odds of subsequent bacteremia [adjusted odds ratio (95% CI) = 2.37 (1.01–5.56)]. The analyses using a propensity score-matched cohort showed consistent results. CONCLUSIONS: Early corticosteroid treatment was associated with a significantly increased hospital mortality in adult patients with influenza-associated ARDS. Earlier treatment and higher dosing were associated with higher hospital mortality. Clinicians should be cautious while using corticosteroid treatment in this patient group.
has issue date	2020-02-27(xsd:dateTime)
bibo:doi	10.1186/s13613-020-0642-4
bibo:pmid	32107651
has license	cc-by
sha1sum (hex)	4790d0413058bafd13761cfe8c9d7083ed54d595
schema:url	https://doi.org/10.1186/s13613-020-0642-4
resource representing a document's title	Impact of corticosteroid treatment on clinical outcomes of influenza-associated ARDS: a nationwide multicenter study
has PubMed Central identifier	PMC7046839
has PubMed identifier	32107651
schema:publication	Ann Intensive Care
resource representing a document's body	covid:4790d0413058bafd13761cfe8c9d7083ed54d595#body_text
is schema:about of	named entity 'ICU' named entity '2015' named entity 'REAL' named entity 'ITS' named entity 'RECEIVED' named entity 'HYDROCORTISONE' covid:arg/4790d0413058bafd13761cfe8c9d7083ed54d595 named entity 'multivariable' named entity 'admission' named entity 'days' named entity 'patients' named entity 'studies' named entity 'Between' named entity 'corticosteroid' named entity 'cohort' named entity 'propensity score' named entity 'Corticosteroid' named entity 'septic shock' named entity 'equivalent dose' named entity 'ARDS' named entity 'ARDS' named entity 'confidence intervals' named entity 'influenza' named entity 'dose-dependent' named entity 'critical illness' named entity 'risk factor' named entity 'prospective studies' named entity 'Cox proportional hazards regression' named entity 'ARDS' named entity 'vasopressor' named entity 'odds ratio' named entity 'septic shock' named entity 'corticosteroid' named entity 'ICU' named entity 'vasopressor' named entity 'inflammation' named entity 'corticosteroid' named entity 'pneumonitis' named entity 'equivalent dose' named entity 'RCT' named entity 'influenza' named entity 'corticosteroid' named entity 'ICUs' named entity 'ICU' named entity 'ARDS' named entity '95% CI' named entity 'prednisone' named entity 'corticosteroid' named entity 'ARDS' named entity 'ECMO' named entity 'systemic corticosteroids' named entity 'ICU' named entity 'H1N1' named entity '57.7%' named entity 'corticosteroid' named entity 'pandemic influenza' named entity 'SAS' named entity 'CAP' named entity 'hazard ratio' named entity 'corticosteroid' named entity 'RCT' named entity 'randomized controlled trials' named entity 'vasopressor' named entity 'ARDS' named entity 'corticosteroid'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software